Ruconest (recombinant C1 esterase inhibitor)

Ruconest is covered only for acute HAE attacks due to C1‑INH deficiency (type I or II) and excluded for prophylaxis/other non‑acute uses, with required baseline labs showing functional C1‑INH <50% of normal and low serum C4. It must be prescribed by or in consultation with an allergist/immunologist or HAE specialist, is approved for 12 months, dosed 50 U/kg if <84 kg or 4200 U if ≥84 kg (one repeat dose allowed, max 4200 U per dose, ≤2 doses/24 hrs), and reauthorization requires prior Ruconest use with documentation of a favorable clinical response.

"Treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.